Claims

1. Use of montelukast or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of:
   (a) an immunodeficiency disorder,
   (b) a condition characterized by immunosuppression, and/or
   (c) a patient with a compromised immune system.

2. The use as claimed in Claim 1, wherein the immunodeficiency disorder and/or condition characterized by immunosuppression is a primary immunodeficiency disorder, selected from the group: a humoral immunodeficiency disorder, a cellular immunodeficiency disorder, a combined humoral and cellular immunodeficiency disorder, a phagocytic immunodeficiency and/or a complement deficiency.

3. The use as claimed in Claim 1, wherein the immunodeficiency disorder and/or condition characterized by immunosuppression is a secondary immunodeficiency disorder.

4. The use as claimed in Claim 3, wherein the disorder is caused by one or more of the group: old age, malnutrition, a chronic disorder, one or more drugs and/or radiation.

5. The use as claimed in Claim 4, wherein the chronic disorder causing immunosuppression is selected from the group: a cancer and/or a disorder of the blood selected from the group: aplastic anemia, a leukemia, multiple myeloma and sickle cell disease; Down's syndrome; a viral infection; a bacterial infection; diabetes mellitus; chronic kidney disease; nephrotic syndrome; chronic hepatitis; liver failure; systemic lupus erythematosus; alcoholism; a chronic burn and/or an operation.

6. The use as claimed in Claim 4, wherein the one or more drugs is selected from the group: an antiseizure drug, an immunosuppressant a biologic, a chemotherapy drug and/or a corticosteroid.

7. The use as claimed in Claim 4, wherein the radiation is radiation therapy administered during the treatment of a disorder.

8. Use of montelukast or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a condition characterized by inflammation and/or wounding in a patient that has, or is vulnerable to, a suppressed immune system.

9. The use as claimed in Claim 8 wherein the montelukast or pharmaceutically acceptable salt thereof provides an immunorestorative effect at the same time as promoting recovery and/or healing of wounds that are associated with said condition.

10. The use as claimed in Claim 8 or Claim 9, wherein the montelukast or pharmaceutically acceptable salt thereof provides an antiinflammatory effect without compromising the patient's immune system.

11. The use as claimed in any one of Claims 8 to 10, wherein the immunosuppression is brought on by radiation therapy administered during the treatment of a disorder.

12. The use as claimed in Claim 7 or Claim 11, wherein the disorder being treated by the radiation therapy is cancer.

13. The use as claimed in any one of Claims 7, 11 or 12, wherein the radiation therapy is targeted to the lower abdomen.

14. The use as claimed in any one of Claims 8 to 13, wherein the condition characterized by inflammation is selected from the group: radiation enteritis, radiation colitis, radiation hepatitis, radiation myelitis, radiation vaginitis and radiation proctitis.

15. The use as claimed in Claim 14, wherein the disorder is radiation proctitis and/or comprises one or more of the group: acute radiation proctitis, radiation colitis, radiation associated vascular ectasias and/or chronic radiation proctopathy.

16. The use as claimed in any one of the preceding claims wherein the montelukast or pharmaceutically acceptable salt thereof is applied locally and topically.

17. The use as claimed in Claim 16 wherein the montelukast is applied in the form of a gel.

18. The use as claimed in Claim 16 or Claim 17, wherein the local, topical application is anorectal.

19. The use as claimed in any one of the preceding claims, wherein the pharmaceutically acceptable salt of montelukast is montelukast sodium.